Skip to search formSkip to main contentSkip to account menu

Ibrutinib 140 MG Oral Capsule [Imbruvica]

Known as: Imbruvica 140 MG Oral Capsule 
National Institutes of Health

Related topics

Related topics

9 relations
Croscarmellose SodiumIbrutinibImbruvicaMagnesium stearate

Broader (2)

Ibrutinib 140 MG Oral CapsuleIbrutinib Oral Capsule [Imbruvica]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Horizon Scanning in Oncology Ibrutinib ( Imbruvica ® ) in combination with rituximab for the treatment of Waldenström ’ s macroglobulinemia
  • 2019
  • Corpus ID: 195060994
2018
2018
Ibrutinib (Imbruvica®) for cGVHD
2018
2018
Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström’s macroglobulinaemia
Constitutive Bruton tyrosine kinase (BTK) activation is associated with B-cell proliferation and lymphoma progression. Ibrutinib… 
2017
2017
Ibrutinib „first line“ in der CLL-Therapie
In einer Phase-III-Studie wurde der Brutontyrosinkinaseinhibitor Ibrutinib (Imbruvica®) als Erstlinientherapie für CLL-Patienten… 
2016
2016
Ibrutinib repurposing: from B-cell malignancies to solid tumors
Ibrutinib (Imbruvica®, also known as PCI-32765) is a first-in-class, irreversible small-molecule inhibitor of Bruton's Tyrosine… 
2016
2016
ibrutinib (IMBRUVICA°) and Waldenström's macroglobulinaemia.
  • Prescrire international
  • 2016
  • Corpus ID: 58620922
The only available trial, a non-comparative study with 63 patients, failed to determine the efficacy of ibrutinib. In contrast… 
2015
2015
Abstract 251: Combining Ibrutinib with immune checkpoint blockade to induce therapeutic antitumor immune response in solid tumors
The ability of T-cell responses to effectively attack tumors is restricted by multiple negative checkpoint regulators. Monoclonal… 
2015
2015
Ibrutinib : applications cliniques et perspectives de développement dans les hémopathies malignes B
Review
2015
Review
2015
[Ibrutinib: A new drug of B-cell malignancies].
2014
2014
Ibrutinib (Imbruvica®) for relapsed or refractory chronic lymphocytic leukaemia
Ibrutinib is a first-in-class, small-molecule inhibitor of Bruton’s Tyrosine Kinase (BTK). Based on the results of the RESONATE… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)